Simcere Zaiming Pharmaceutical is a biopharma firm and a subsidiary of Hong Kong-listed branded generic player Simcere Pharmaceutical Group. The company operates in the biopharmaceutical sector. The article does not provide details on specific products, pipeline, revenue, users, or future plans. Financially, Simcere Zaiming raised 970 million yuan (approximately $134.8 million) in a recent equity financing round. The round was led by FIIF, a fund managed by CS Capital. No additional investors or the intended use of proceeds were disclosed in the article.

Total raised

$135M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2024